These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 38845302)
1. Cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for the pediatric population in South Korea. Kang DW; June Choe Y; Lee JY; Suk IA; Kim YS; Kim HY; Byun BK; Park SK Vaccine; 2024 Jun; ():. PubMed ID: 38845302 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis. Ta A; Kühne F; Laurenz M; von Eiff C; Warren S; Perdrizet J Infect Dis Ther; 2024 Jun; 13(6):1333-1358. PubMed ID: 38733494 [TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults. Rey-Ares L; Averin A; Mac Mullen M; Hariharan D; Atwood M; Carballo C; Huang L Infect Dis Ther; 2024 Jun; 13(6):1235-1251. PubMed ID: 38700655 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of the 20-valent pneumococcal conjugate vaccine versus the 23-valent pneumococcal polysaccharide vaccine for older adults in South Korea. Kang DW; Kim CR; Song JY; Park SK Vaccine; 2024 Feb; 42(4):871-878. PubMed ID: 38225184 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of PCV20 to prevent pneumococcal disease in the Canadian pediatric population. Lytle D; Grajales Beltrán AG; Perdrizet J; Ait Yahia N; Cane A; Yarnoff B; Chapman R Hum Vaccin Immunother; 2023 Aug; 19(2):2257426. PubMed ID: 37771288 [TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of the pediatric 20-valent pneumococcal conjugate vaccine compared with lower-valent alternatives in Argentina. Rey-Ares L; Ta A; Freigofaite D; Warren S; Mac Mullen M; Carballo C; Huang L Vaccine; 2024 Jun; ():. PubMed ID: 38879409 [TBL] [Abstract][Full Text] [Related]
7. Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States. Huang L; Wasserman M; Grant L; Farkouh R; Snow V; Arguedas A; Chilson E; Sato R; Perdrizet J Vaccine; 2022 Aug; 40(33):4700-4708. PubMed ID: 35753839 [TBL] [Abstract][Full Text] [Related]
8. 20-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults. Shirley M Drugs; 2022 Jun; 82(9):989-999. PubMed ID: 35793027 [TBL] [Abstract][Full Text] [Related]
10. Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age. Wasserman MD; Perdrizet J; Grant L; Hayford K; Singh S; Saharia P; Horn EK; Farkouh RA Infect Dis Ther; 2021 Dec; 10(4):2701-2720. PubMed ID: 34633639 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine for routine pediatric vaccination programs in Japan. Shinjoh M; Togo K; Hayamizu T; Yonemoto N; Morii J; Perdrizet J; Kamei K Expert Rev Vaccines; 2024; 23(1):485-497. PubMed ID: 38682661 [TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness Analysis of the South African Infant National Immunization Program for the Prevention of Pneumococcal Disease. Huang L; McDade CL; Perdrizet JE; Wilson MR; Warren SA; Nzenze S; Sewdas R Infect Dis Ther; 2023 Mar; 12(3):933-950. PubMed ID: 36774428 [TBL] [Abstract][Full Text] [Related]
13. Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines V114 and PCV20 against invasive pneumococcal disease in children. Ryman J; Sachs JR; Yee KL; Banniettis N; Weaver J; Weiss T Expert Rev Vaccines; 2024; 23(1):60-68. PubMed ID: 38073483 [TBL] [Abstract][Full Text] [Related]
14. A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults ≥ 60 years of age in Japan, South Korea, and Taiwan. Haranaka M; Young Song J; Huang KC; de Solom R; Yamaji M; McElwee K; Kline M; Aizawa M; Peng Y; Scully I; Kogawara O; Gruber WC; Scott DA; Watson W Vaccine; 2024 Feb; 42(5):1071-1077. PubMed ID: 38267330 [TBL] [Abstract][Full Text] [Related]
15. Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece. Gourzoulidis G; Barmpouni M; Kossyvaki V; Vietri J; Tzanetakos C Front Public Health; 2023; 11():1229524. PubMed ID: 37841729 [TBL] [Abstract][Full Text] [Related]
16. Estimating the Cost-Effectiveness of Switching to Higher-Valency Pediatric Pneumococcal Conjugate Vaccines in the United Kingdom. Wilson M; Lucas A; Mendes D; Vyse A; Mikudina B; Czudek C; Ellsbury GF; Perdrizet J Vaccines (Basel); 2023 Jun; 11(7):. PubMed ID: 37514984 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in Denmark compared with PPV23. Olsen J; Schnack H; Skovdal M; Vietri J; Mikkelsen MB; Poulsen PB J Med Econ; 2022; 25(1):1240-1254. PubMed ID: 36426797 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness and impact on infections and associated antimicrobial resistance of 20-valent pneumococcal conjugate vaccine in US children previously immunized with PCV13. Rozenbaum MH; Huang L; Cane A; Arguedas A; Chapman R; Dillon-Murphy D; Tort MJ; Snow V; Chilson E; Farkouh R J Med Econ; 2024; 27(1):644-652. PubMed ID: 38577742 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea. Kim HY; Park SB; Kang ES; Lee SM; Kim HJ; Wasserman M Hum Vaccin Immunother; 2021 Mar; 17(3):909-918. PubMed ID: 32783576 [TBL] [Abstract][Full Text] [Related]
20. Budgetary Impact of 20-Valent Pneumococcal Conjugate Vaccine Use for Adult Expatriates Living in Dubai. Zayed M; Joury J; Farghaly M; Al Dallal S; Mahboub B; Kutrieb E; Averin A Curr Ther Res Clin Exp; 2023; 98():100698. PubMed ID: 37096181 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]